LON:UPR

Uniphar PLC

OPPORTUNISTIC BUY Analysis generated 2026-10-04 Market data as of 2026-11-13 Market data 2 days old 364.00p Healthcare - Medical - DistributionREDUCE ZONE

ACTIONABLEMethodology gates passed

Position levels

Currenttoday

364.00p

Buy <=wait / entry

306.67p

Trim >=take some off

360.00p

Thesis breakLoss of the named Citius LYMPHIR supply agreement, or a sustained breach of the ...

Scenario-weighted conviction

	Probability	Score	Contribution
Bull case	26%	100 / 100	26.0
Base case	49%	62 / 100	30.4
Bear case	25%	10 / 100	2.5
Weighted conviction			59 / 100 - OPPORTUNISTIC BUY

Top risks

Exclusive distribution agreement with Citius Oncology for LYMPHIR in Western and Eastern Europe
H1 2026 results with 7.2% revenue growth to EUR 1.59bn, 11.2% adjusted EPS growth to 10.9 cent, and on track for EUR 200m EBITDA by 2028
Analyst consensus Strong Buy with 1y targets of 5.57 EUR / 415.68 GBp materially above current prices

Read full report →

Research is for informational purposes only. Not financial advice. All analysis reflects the date of publication.